Schade – dieser Artikel ist leider ausverkauft. Sobald wir wissen, ob und wann der Artikel wieder verfügbar ist, informieren wir Sie an dieser Stelle.
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Early characterization of toxicity and efficacy would significantly impact the overall productivity of pharmaceutical R&D and reduce drug candidate attrition and failure. By describing the available platforms and weighing their relative advantages and disadvantages, including microarray data analysis, Genomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, and toxicogenomics toolbox. The authors provide a valuable resource for pharmaceutical discovery scientists, preclinical drug safety department personnel, regulatory personnel, discovery…mehr
- Geräte: PC
- eBook Hilfe
Early characterization of toxicity and efficacy would significantly impact the overall productivity of pharmaceutical R&D and reduce drug candidate attrition and failure. By describing the available platforms and weighing their relative advantages and disadvantages, including microarray data analysis, Genomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, and toxicogenomics toolbox. The authors provide a valuable resource for pharmaceutical discovery scientists, preclinical drug safety department personnel, regulatory personnel, discovery toxicologists, and safety scientists, drug development professionals, and pharmaceutical scientists.
Produktdetails
- Produktdetails
- Verlag: John Wiley & Sons
- Seitenzahl: 480
- Erscheinungstermin: 11. November 2008
- Englisch
- ISBN-13: 9780470409763
- Artikelnr.: 37291996
- Verlag: John Wiley & Sons
- Seitenzahl: 480
- Erscheinungstermin: 11. November 2008
- Englisch
- ISBN-13: 9780470409763
- Artikelnr.: 37291996
Dimitri Semizarov, PhD, is a Senior Group Leader in the Cancer Research Department of Abbott Laboratories' Global Pharmaceutical R&D. Dr. Semizarov leads cancer genomics research at Abbott, applying genomics technologies to enable personalization of cancer therapy. He is author or coauthor of more than twenty scientific articles and eight patent applications, as well as three book chapters (including two chapters in Wiley's Preclinical Development Handbook). Eric Blomme, DVM, PhD, Diplomate, American College of Veterinary Pathologists, is a Senior Project Leader for Cellular, Molecular, and Exploratory Toxicology in Global Pharmaceutical R&D at Abbott Laboratories. He has extensive drug discovery, toxicology, and screening experience working for Abbott, Pharmacia, Monsanto, Searle, Ohio State University, and Cornell University. Dr. Blomme has written over fifty journal articles and eight book chapters, and is a reviewer for multiple scientific journals in the fields of toxicology and pathology.
Preface. Chapter 1: Introduction: Genomics and Personalized Medicine
(Dimitri Semizarov). 1.1. Fundamentals of genomics. 1.2. The concept of
personalized medicine. 1.3. Genomics technologies in drug discovery. 1.4.
Scope of this book. References. Chapter 2: Genomics Technologies as Tools
in Drug Discovery (Dimitri Semizarov). 2.1. Introduction to genomics
technologies. 2.2. Gene expression microarrays: technology. 2.3. Gene
expression microarrays: data analysis. 2.4. Comparative genomic
hybridization: technology. 2.5. Comparative genomic hybridization: data
analysis. 2.6. Microarray-based DNA methylation profiling. 2.7.
Microarray-based microRNA profiling. 2.8. Technical issues in genomics
experiments and regulatory submissions of microarray data. 2.9. Conclusion.
References. Chapter 3: Genomic Biomarkers (Dimitri Semizarov). 3.1.
Introduction into genomic biomarkers. 3.2. DNA biomarkers. 3.3. RNA
biomarkers. 3.4. Clinical validation of genomic biomarkers. References.
Chapter 4: Fundamental Principles of Toxicogenomics (Eric Blomme). 4.1.
Introduction. 4.2. Fundamentals of toxicogenomics. 4.3. Analysis of
toxicogenomics data. 4.4. Practical and logistic aspects of toxicogenomics.
4.5. Toxicogenomics reference databases. 4.6. Conclusion. References.
Chapter 5: Toxicogenomics: Applications to In Vivo Toxicology (Eric
Blomme). 5.1. The value of toxicogenomics in drug discovery and
development. 5.2. Basic principles of toxicology in drug discovery and
development. 5.3. Toxicogenomics in predictive toxicology. 5.4.
Toxicogenomics in mechanistic toxicology. 5.5. Toxicogenomics and
target-related toxicity. 5.6. Predicting species-specific toxicity. 5.7.
Evaluation of idiosyncratic toxicity with toxicogenomics. 5.8. Conclusion.
References. Chapter 6: Toxicogenomics: Applications in In Vitro Systems
(Eric Blomme). 6.1. Introductory remarks on in vitro toxicology. 6.2.
Overview of the current approaches to in vitro toxicology. 6.3.
Toxicogenomics in in vitro systems: technical considerations. 6.4.
Proof-of-concept studies using primary rat hepatocytes. 6.5. Use of gene
expression profiling to assess genotoxicity. 6.6. Application of gene
expression profiling for the in vitro detection of phopholipidosis. 6.7.
Toxicogenomics in the assessment of idiosyncratic hepatotoxicity. 6.8. Do
peripheral blood mononuclear cells represent a useful alternative in vitro
model? 6.9. Current and future use of in vitro toxicogenomics. 6.10.
Conclusion. References. Chapter 7: Germ Line Polymorphisms and Drug
Response (Dimitri Semizarov). 7.1. Introduction into germline
polymorphisms. 7.2. Polymorphisms and drug response in oncology. 7.3.
Polymorphisms and response to anticoagulants. 7.4. Polymorphisms in
neuroscience. 7.5. Polymorphisms and drug response in immunology. 7.6.
Polymorphisms and response to antiviral agents. 7.7. Gene copy number
polymorphisms. 7.8. Conclusions: approaches to identification of
polymorphisms as predictors of drug response. References. Chapter 8:
Pharmacogenetics of Drug Disposition (Anahita Bhathena). 8.1. Introduction.
8.2. Genes and polymorphisms affecting drug disposition. 8.3. Genomic
biomarkers for PK studies. 8.4. Utility of PG--PK studies in early clinical
trials. 8.5. Limitations of PG--PK studies. 8.6. Genotyping technologies.
8.7. Conclusion. References. Chapter 9: Overview of Regulatory Developments
and Initiatives Related to the Use of Genomic Technologies in Drug
Discovery and Development (Eric Blomme). 9.1. Introduction into recent
regulatory developments in the genomic area. 9.2. FDA guidance on
pharmacogenomic data submission. 9.3. Pharmacogenomic data submission:
draft companion guidance. 9.4. Drug-diagnostic co-development concept
paper. 9.5. Regulations for in vitro diagnostic assays. 9.6. Biomarker
qualification. 9.7. Current initiatives relevant to pharmacogenomics. 9.8.
Future impact of genomic data on drug development. References. Index.
(Dimitri Semizarov). 1.1. Fundamentals of genomics. 1.2. The concept of
personalized medicine. 1.3. Genomics technologies in drug discovery. 1.4.
Scope of this book. References. Chapter 2: Genomics Technologies as Tools
in Drug Discovery (Dimitri Semizarov). 2.1. Introduction to genomics
technologies. 2.2. Gene expression microarrays: technology. 2.3. Gene
expression microarrays: data analysis. 2.4. Comparative genomic
hybridization: technology. 2.5. Comparative genomic hybridization: data
analysis. 2.6. Microarray-based DNA methylation profiling. 2.7.
Microarray-based microRNA profiling. 2.8. Technical issues in genomics
experiments and regulatory submissions of microarray data. 2.9. Conclusion.
References. Chapter 3: Genomic Biomarkers (Dimitri Semizarov). 3.1.
Introduction into genomic biomarkers. 3.2. DNA biomarkers. 3.3. RNA
biomarkers. 3.4. Clinical validation of genomic biomarkers. References.
Chapter 4: Fundamental Principles of Toxicogenomics (Eric Blomme). 4.1.
Introduction. 4.2. Fundamentals of toxicogenomics. 4.3. Analysis of
toxicogenomics data. 4.4. Practical and logistic aspects of toxicogenomics.
4.5. Toxicogenomics reference databases. 4.6. Conclusion. References.
Chapter 5: Toxicogenomics: Applications to In Vivo Toxicology (Eric
Blomme). 5.1. The value of toxicogenomics in drug discovery and
development. 5.2. Basic principles of toxicology in drug discovery and
development. 5.3. Toxicogenomics in predictive toxicology. 5.4.
Toxicogenomics in mechanistic toxicology. 5.5. Toxicogenomics and
target-related toxicity. 5.6. Predicting species-specific toxicity. 5.7.
Evaluation of idiosyncratic toxicity with toxicogenomics. 5.8. Conclusion.
References. Chapter 6: Toxicogenomics: Applications in In Vitro Systems
(Eric Blomme). 6.1. Introductory remarks on in vitro toxicology. 6.2.
Overview of the current approaches to in vitro toxicology. 6.3.
Toxicogenomics in in vitro systems: technical considerations. 6.4.
Proof-of-concept studies using primary rat hepatocytes. 6.5. Use of gene
expression profiling to assess genotoxicity. 6.6. Application of gene
expression profiling for the in vitro detection of phopholipidosis. 6.7.
Toxicogenomics in the assessment of idiosyncratic hepatotoxicity. 6.8. Do
peripheral blood mononuclear cells represent a useful alternative in vitro
model? 6.9. Current and future use of in vitro toxicogenomics. 6.10.
Conclusion. References. Chapter 7: Germ Line Polymorphisms and Drug
Response (Dimitri Semizarov). 7.1. Introduction into germline
polymorphisms. 7.2. Polymorphisms and drug response in oncology. 7.3.
Polymorphisms and response to anticoagulants. 7.4. Polymorphisms in
neuroscience. 7.5. Polymorphisms and drug response in immunology. 7.6.
Polymorphisms and response to antiviral agents. 7.7. Gene copy number
polymorphisms. 7.8. Conclusions: approaches to identification of
polymorphisms as predictors of drug response. References. Chapter 8:
Pharmacogenetics of Drug Disposition (Anahita Bhathena). 8.1. Introduction.
8.2. Genes and polymorphisms affecting drug disposition. 8.3. Genomic
biomarkers for PK studies. 8.4. Utility of PG--PK studies in early clinical
trials. 8.5. Limitations of PG--PK studies. 8.6. Genotyping technologies.
8.7. Conclusion. References. Chapter 9: Overview of Regulatory Developments
and Initiatives Related to the Use of Genomic Technologies in Drug
Discovery and Development (Eric Blomme). 9.1. Introduction into recent
regulatory developments in the genomic area. 9.2. FDA guidance on
pharmacogenomic data submission. 9.3. Pharmacogenomic data submission:
draft companion guidance. 9.4. Drug-diagnostic co-development concept
paper. 9.5. Regulations for in vitro diagnostic assays. 9.6. Biomarker
qualification. 9.7. Current initiatives relevant to pharmacogenomics. 9.8.
Future impact of genomic data on drug development. References. Index.
Preface. Chapter 1: Introduction: Genomics and Personalized Medicine
(Dimitri Semizarov). 1.1. Fundamentals of genomics. 1.2. The concept of
personalized medicine. 1.3. Genomics technologies in drug discovery. 1.4.
Scope of this book. References. Chapter 2: Genomics Technologies as Tools
in Drug Discovery (Dimitri Semizarov). 2.1. Introduction to genomics
technologies. 2.2. Gene expression microarrays: technology. 2.3. Gene
expression microarrays: data analysis. 2.4. Comparative genomic
hybridization: technology. 2.5. Comparative genomic hybridization: data
analysis. 2.6. Microarray-based DNA methylation profiling. 2.7.
Microarray-based microRNA profiling. 2.8. Technical issues in genomics
experiments and regulatory submissions of microarray data. 2.9. Conclusion.
References. Chapter 3: Genomic Biomarkers (Dimitri Semizarov). 3.1.
Introduction into genomic biomarkers. 3.2. DNA biomarkers. 3.3. RNA
biomarkers. 3.4. Clinical validation of genomic biomarkers. References.
Chapter 4: Fundamental Principles of Toxicogenomics (Eric Blomme). 4.1.
Introduction. 4.2. Fundamentals of toxicogenomics. 4.3. Analysis of
toxicogenomics data. 4.4. Practical and logistic aspects of toxicogenomics.
4.5. Toxicogenomics reference databases. 4.6. Conclusion. References.
Chapter 5: Toxicogenomics: Applications to In Vivo Toxicology (Eric
Blomme). 5.1. The value of toxicogenomics in drug discovery and
development. 5.2. Basic principles of toxicology in drug discovery and
development. 5.3. Toxicogenomics in predictive toxicology. 5.4.
Toxicogenomics in mechanistic toxicology. 5.5. Toxicogenomics and
target-related toxicity. 5.6. Predicting species-specific toxicity. 5.7.
Evaluation of idiosyncratic toxicity with toxicogenomics. 5.8. Conclusion.
References. Chapter 6: Toxicogenomics: Applications in In Vitro Systems
(Eric Blomme). 6.1. Introductory remarks on in vitro toxicology. 6.2.
Overview of the current approaches to in vitro toxicology. 6.3.
Toxicogenomics in in vitro systems: technical considerations. 6.4.
Proof-of-concept studies using primary rat hepatocytes. 6.5. Use of gene
expression profiling to assess genotoxicity. 6.6. Application of gene
expression profiling for the in vitro detection of phopholipidosis. 6.7.
Toxicogenomics in the assessment of idiosyncratic hepatotoxicity. 6.8. Do
peripheral blood mononuclear cells represent a useful alternative in vitro
model? 6.9. Current and future use of in vitro toxicogenomics. 6.10.
Conclusion. References. Chapter 7: Germ Line Polymorphisms and Drug
Response (Dimitri Semizarov). 7.1. Introduction into germline
polymorphisms. 7.2. Polymorphisms and drug response in oncology. 7.3.
Polymorphisms and response to anticoagulants. 7.4. Polymorphisms in
neuroscience. 7.5. Polymorphisms and drug response in immunology. 7.6.
Polymorphisms and response to antiviral agents. 7.7. Gene copy number
polymorphisms. 7.8. Conclusions: approaches to identification of
polymorphisms as predictors of drug response. References. Chapter 8:
Pharmacogenetics of Drug Disposition (Anahita Bhathena). 8.1. Introduction.
8.2. Genes and polymorphisms affecting drug disposition. 8.3. Genomic
biomarkers for PK studies. 8.4. Utility of PG--PK studies in early clinical
trials. 8.5. Limitations of PG--PK studies. 8.6. Genotyping technologies.
8.7. Conclusion. References. Chapter 9: Overview of Regulatory Developments
and Initiatives Related to the Use of Genomic Technologies in Drug
Discovery and Development (Eric Blomme). 9.1. Introduction into recent
regulatory developments in the genomic area. 9.2. FDA guidance on
pharmacogenomic data submission. 9.3. Pharmacogenomic data submission:
draft companion guidance. 9.4. Drug-diagnostic co-development concept
paper. 9.5. Regulations for in vitro diagnostic assays. 9.6. Biomarker
qualification. 9.7. Current initiatives relevant to pharmacogenomics. 9.8.
Future impact of genomic data on drug development. References. Index.
(Dimitri Semizarov). 1.1. Fundamentals of genomics. 1.2. The concept of
personalized medicine. 1.3. Genomics technologies in drug discovery. 1.4.
Scope of this book. References. Chapter 2: Genomics Technologies as Tools
in Drug Discovery (Dimitri Semizarov). 2.1. Introduction to genomics
technologies. 2.2. Gene expression microarrays: technology. 2.3. Gene
expression microarrays: data analysis. 2.4. Comparative genomic
hybridization: technology. 2.5. Comparative genomic hybridization: data
analysis. 2.6. Microarray-based DNA methylation profiling. 2.7.
Microarray-based microRNA profiling. 2.8. Technical issues in genomics
experiments and regulatory submissions of microarray data. 2.9. Conclusion.
References. Chapter 3: Genomic Biomarkers (Dimitri Semizarov). 3.1.
Introduction into genomic biomarkers. 3.2. DNA biomarkers. 3.3. RNA
biomarkers. 3.4. Clinical validation of genomic biomarkers. References.
Chapter 4: Fundamental Principles of Toxicogenomics (Eric Blomme). 4.1.
Introduction. 4.2. Fundamentals of toxicogenomics. 4.3. Analysis of
toxicogenomics data. 4.4. Practical and logistic aspects of toxicogenomics.
4.5. Toxicogenomics reference databases. 4.6. Conclusion. References.
Chapter 5: Toxicogenomics: Applications to In Vivo Toxicology (Eric
Blomme). 5.1. The value of toxicogenomics in drug discovery and
development. 5.2. Basic principles of toxicology in drug discovery and
development. 5.3. Toxicogenomics in predictive toxicology. 5.4.
Toxicogenomics in mechanistic toxicology. 5.5. Toxicogenomics and
target-related toxicity. 5.6. Predicting species-specific toxicity. 5.7.
Evaluation of idiosyncratic toxicity with toxicogenomics. 5.8. Conclusion.
References. Chapter 6: Toxicogenomics: Applications in In Vitro Systems
(Eric Blomme). 6.1. Introductory remarks on in vitro toxicology. 6.2.
Overview of the current approaches to in vitro toxicology. 6.3.
Toxicogenomics in in vitro systems: technical considerations. 6.4.
Proof-of-concept studies using primary rat hepatocytes. 6.5. Use of gene
expression profiling to assess genotoxicity. 6.6. Application of gene
expression profiling for the in vitro detection of phopholipidosis. 6.7.
Toxicogenomics in the assessment of idiosyncratic hepatotoxicity. 6.8. Do
peripheral blood mononuclear cells represent a useful alternative in vitro
model? 6.9. Current and future use of in vitro toxicogenomics. 6.10.
Conclusion. References. Chapter 7: Germ Line Polymorphisms and Drug
Response (Dimitri Semizarov). 7.1. Introduction into germline
polymorphisms. 7.2. Polymorphisms and drug response in oncology. 7.3.
Polymorphisms and response to anticoagulants. 7.4. Polymorphisms in
neuroscience. 7.5. Polymorphisms and drug response in immunology. 7.6.
Polymorphisms and response to antiviral agents. 7.7. Gene copy number
polymorphisms. 7.8. Conclusions: approaches to identification of
polymorphisms as predictors of drug response. References. Chapter 8:
Pharmacogenetics of Drug Disposition (Anahita Bhathena). 8.1. Introduction.
8.2. Genes and polymorphisms affecting drug disposition. 8.3. Genomic
biomarkers for PK studies. 8.4. Utility of PG--PK studies in early clinical
trials. 8.5. Limitations of PG--PK studies. 8.6. Genotyping technologies.
8.7. Conclusion. References. Chapter 9: Overview of Regulatory Developments
and Initiatives Related to the Use of Genomic Technologies in Drug
Discovery and Development (Eric Blomme). 9.1. Introduction into recent
regulatory developments in the genomic area. 9.2. FDA guidance on
pharmacogenomic data submission. 9.3. Pharmacogenomic data submission:
draft companion guidance. 9.4. Drug-diagnostic co-development concept
paper. 9.5. Regulations for in vitro diagnostic assays. 9.6. Biomarker
qualification. 9.7. Current initiatives relevant to pharmacogenomics. 9.8.
Future impact of genomic data on drug development. References. Index.
?This book is highly recommended to active researchers in genomics and to the comparative and veterinary clinician or researchers looking for a focused review of the emerging discipline.? ( The Veterinary Journal , August 2009)
?Overall, it provides excellent, up-to-date coverage of the application of genomics in drug development.? ( Doody s Reviews , June 2009)
?Overall, it provides excellent, up-to-date coverage of the application of genomics in drug development.? ( Doody s Reviews , June 2009)